Dr. Timothy M. Schmidt, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Saint Louis University School of Medicine (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 178
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: Saint Louis University School of Medicine
- 2014Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
WI license 73575
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Wi Hospitals & Clinics Authority Madison, WI
- Aurora St Lukes Medical Center Milwaukee, WI
- Southwest Health Center Platteville, WI
Medical groups
- University of Wisconsin Medical Foundation Inc (2,553 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 178
- Services billed
- 819
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 159 | 57 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 153 | 34 |
| Established patient office or other outpatient visit, 30-39 minutes | 134 | 54 |
| Insertion of needle into vein for collection of blood sample | 31 | 15 |
| Established patient office or other outpatient visit, 20-29 minutes | 22 | 18 |
| Hospital discharge day management, 30 minutes or less | 19 | 17 |
| Telephone medical discussion with physician, 5-10 minutes | 16 | 12 |
| New patient office or other outpatient visit, 60-74 minutes | 15 | 15 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Madison, WI | 238 |
| Revlimid (lenalidomide) | 143 |
| Lenalidomide | 118 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Madison, WI | 94 |
| Dexamethasone Other prescribers in Madison, WI | 91 |
| Ondansetron Hcl Other prescribers in Madison, WI | 45 |
| Tamsulosin Hcl Other prescribers in Madison, WI | 34 |
| Pomalyst (pomalidomide) | 33 |
| Duloxetine Hcl Other prescribers in Madison, WI | 31 |
| Eliquis (apixaban) Other prescribers in Madison, WI | 28 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $554,976 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Par…
Janssen Research & Development, LLC - A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients with Stage IIIa AL Ca…
Alexion Pharmaceuticals, Inc. - A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Par…
Janssen Research & Development, LLC - A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refract…
Celgene Corporation - Frontline t cell engager vs autologous stem cell transplant and measurable residual disease mrdguided sequential intensification therapy in multiple myeloma faster
Pfizer Inc. - A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refract…
E.r. Squibb & Sons, L.l.c. - A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients with Stage IIIb AL Cardi…
Alexion Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.